Simplify diabetes management for your patients
Omnipod® 5 Automated Insulin Delivery
A wearable, tubeless, hybrid closed loop system with sensor integration (Dexcom G7 and FreeStyle Libre 2 Plus) for people with type 1 diabetes (T1D) aged 2 years and older requiring insulin.
Compatible with Dexcom G7 and FreeStyle Libre 2 Plus
- Your patients can experience the freedom of automated insulin delivery with glucose sensor and Omnipod 5
- SmartAdjust™ Technology adjusts basal insulin delivery, every five minutes, so you don’t have to.** It proactively helps to correct highs and protect from lows.1,2
- Improved HbA1c and time in range across age groups vs prior therapy, while time in hypoglycaemia remained low1,2
System Components
Controller + Pod + Sensor
Screen image is an example, for illustrative purposes only. Pod shown without the necessary adhesive. ∞Compatible with Dexcom G7 and FreeStyle Libre 2 Plus sensors. *Automated mode requires compatible sensor. Compatible sensors are sold and prescribed separately. Sensor availability may vary per country or region.
Omnipod 5’s Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ is Omnipod 5’s automated insulin delivery algorithm. It adjusts basal insulin automatically so there is no need to continuously fine-tune basal settings. The system uses recent total daily insulin history to adapt to changes throughout life like changes in weight, growth and aging.**
Watch this short video to learn more about the technology and how it works.
Diabetes data management, simplified
Experience a smarter way to support your Omnipod® 5 patients. With sensor data, insulin, carbs, usage metrics, and Pod settings all in one place—plus a seamless cloud connection, Omnipod® Discover delivers simple diabetes data all in one report. It continually and automatically collects Omnipod 5 and sensor data wirelessly to help track glucose trends, insulin delivery data, and pump settings all in one report.
So you can optimize your time with your Omnipod 5 patients.
Omnipod DASH® Insulin Management System
Help your patients manage T1D with an easy-to-use insulin delivery system that has demonstrated improvements in glycaemic results.Ω3
Learn more about Pod Therapy and how the Omnipod DASH® Insulin Management System could benefit your patients.
ΩAs seen in real-world studies of people with T1D using the Omnipod DASH® compared to their previous multiple daily injection (MDI) treatment.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod. You can reach us at: 8000320057 or at 600521670 11 or via email at [email protected].
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001). Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hypoglycaemic range (<3.9mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Aleppo G et al. Diabetes Ther. (2023). Retrospective observational study of 4,738 people with T1D in the US before (baseline) and 90 days after (follow-up) initiation of the tubeless Omnipod DASH Insulin Management System, children, adolescents and adults who switched from MDI to Omnipod saw an improvement in HbA1c of -0.9% (8.6 to 7.7% for pediatric participants and 8.5% to 7.6% for adults); Pediatric self-reported hypoglycemia episodes/week improved - 1.3 (2.8 to 1.5) and adult hypoglycemia improved - 1.6 (2.9 to 1.3). All results had p-value <0.0001.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®/NovoRapid®, Humalog®, Admelog®/Insulin lispro Sanofi®, Trurapi®/Insulin aspart Sanofi®, and Kirsty®. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.
The Omnipod DASH® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. Additionally, the Omnipod DASH® System permits manual entry of readings from blood glucose meters, enabling storage and display of blood glucose measurements. The Omnipod® System and Omnipod DASH® System have been tested and found to be suitable for use with the following U-100 insulin: NovoLog®/NovoRapid®, Humalog®, Fiasp®, Lyumjev®, Admelog®/ Insulin lispro Sanofi® and Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Apidra®. Refer to the Omnipod DASH® Insulin Management System User Guides for complete safety information including indications, contraindications, warnings, cautions, and instructions. These User Guides are periodically updated. Visit Omnipod.com to see the most recent version and to find other helpful information. To access these User Guides in other languages, please visit Omnipod.com. DO NOT start using your system or change your settings without adequate training and guidance from your healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or underdelivery of insulin, which could lead to hypoglycemia or hyperglycemia.
Omnipod Discover is a retrospective data analytics and reporting system intended for Omnipod 5 or their caregivers and their healthcare providers for the analysis of glucose and insulin delivery data in home and healthcare settings. It is intended as supplemental data for the users to support diabetes management and aid healthcare providers in patient care. Omnipod Discover is not intended for people with diabetes in acute care settings or for real-time patient monitoring. The Omnipod Discover software platform is not intended to replace the primary real-time display of the sensor or insulin delivery data on the device, nor does it control any functions of the Omnipod System. Any medical treatment decision or adjustments should not be made based on this software platform; a qualified healthcare professional needs to be consulted to make such decisions.
